'If we close, people die': Rural Ontario hospitals await ER staffing certainty
Health Minister Sylvia Jones' office has said it is working on a permanent solution after the temporary program expired, but in the meantime the people who work to keep ERs open are concerned about filling those shifts.
"Because we're so short-staffed, we cannot run a 24-hour emergency department without outside physician support," said Ann Fenlon, the medical recruitment and retention co-ordinator at Lady Dunn Health Centre in Wawa, Ont.
The northern Ontario community is supposed to have seven doctors who provide both family and emergency medicine, but they currently have three, Fenlon said. They have not had to close their ER, but they have come close, she said.
"We're 240 kilometres away from the next hospital," Fenlon said. "If we close, people die."
The Temporary Locum Program pays doctors an incentive to fill emergency department shifts -- with most of those physicians coming from other, more urban parts of the province -- to help hospitals in more isolated areas on a locum, or temporary, basis.
Ontario first established it as a temporary program during the COVID-19 pandemic, but amid broader physician staffing challenges the rural and northern hospitals have come to rely on it.
The Ontario Medical Association's emergency medicine section chair suggested in a recent memo to emergency department leads that staff at several hospitals have been expressing concerns about the current limbo.
"The section is acutely aware of the impact the end of this program will have on staffing stability of emergency departments across the province," Angela Marrocco wrote.
"We have done everything we can to emphasize this reality to the Ministry of Health...The OMA is continuing to pursue ways to mitigate any negative impacts related to timing between expiry of TLP and implementation of a permanent model."
Province working on a permanent program
A spokesperson for Jones said the goal has always been a permanent program, and the ministry is currently in negotiations with the OMA.
"Hospitals can continue to schedule physician coverage as required as we work with the Ontario Medical Association to transition the temporary locum program into a permanent program through the new Physician Services Agreement," Hannah Jensen said.
But the question is not whether hospitals can continue to try to book doctors on a locum basis, said Melanie Goulet, recruitment co-ordinator for health professionals at Notre-Dame Hospital in Hearst, Ont. It's whether there will be funding to incentivize physicians to fill those shifts.
"Obviously (we'll) continue to book them...We don't want to close our emerg," she said.
But at the moment she isn't sure what will happen with the doctors currently in Hearst on a locum basis or those with shifts coming up -- will their additional pay come later, on a retroactive basis? In her region it amounts to almost $900 for a 12-hour shift, so without it she worries recruitment will be hampered.
"We have one physician, she's in Hearst for almost two weeks...and I don't know what to tell her," Goulet said.
"So as much as they say they're clear, I don't think they actually understand the situation."
The ministry also offers an Emergency Department Locum Program, but there are different criteria, and it is mostly for last-minute needs, not allowing co-ordinators to plan too far ahead, Goulet said. Both programs help ERs stay open, she said.
The Temporary Locum Program has been extended several times, in at least one case months after it had already expired. Hospitals just want some certainty, Fenlon said.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


Global News
6 hours ago
- Global News
Charleigh's case: Disease experts ‘strongly oppose' move to cut rare drug funding
A group of experts on Batten disease in the United States has penned a letter to B.C.'s health minister and premier, strongly opposing the decision to withdraw funding for 10-year-old Charleigh Pollock. The letter is signed by the Clinical Directors from the U.S. Batten Disease Clinical Centers of Excellence and Batten Disease Clinical Research Consortium and asks the B.C. government to review the current discontinuation criteria. Pollock has a neurological disorder called Batten disease that leaves her with recurring severe seizures and mobility loss, and will eventually cut her young life short. On June 18, Charleigh's family was informed that government funding of a drug called Brineura, which her family said has stabilized her condition and radically improved her quality of life since her 2019 diagnosis. The drug is expensive, carrying an annual bill for the twice-monthly infusions of about $1 million. Story continues below advertisement Charleigh's family appealed to the B.C. Ministry of Health to reverse the decision and consider more research and speak to more experts. However, the decision was not reversed. 2:00 Review of Charleigh Pollock's case finished The doctors and researchers who wrote the letter say their international colleagues and collaborators Angela Schulz MD and Miriam Nickel MD in Germany were instrumental in developing the clinical outcome measures used to track disease progression in CLN2 disease, which is a type of Batten disease. Get weekly health news Receive the latest medical news and health information delivered to you every Sunday. Sign up for weekly health newsletter Sign Up By providing your email address, you have read and agree to Global News' Terms and Conditions and Privacy Policy 'Drawing from our collective and unparalleled expertise in CLN2 disease, we strongly oppose the decision to withdraw funding for life-sustaining ERT from Charleigh Pollock and call for a review of the current discontinuation criteria,' the letter reads. Prior to 2017, the late-infantile form of CLN2 disease was universally fatal, however, the introduction of intracerebroventricular ERT, which is the medication Pollock was given, 'fundamentally altered the disease trajectory.' Story continues below advertisement The experts said the treatment 'has demonstrably prolonged survival, slowed progression, improved seizure control, and enhanced quality of life.' The B.C. government has always maintained that the decision to stop funding Charliegh's medication was never about money but a panel of experts decided the drug was not helping Charleigh anymore. 'This is a really awful case,' B.C. Premier David Eby said on Thursday. 'This is a beautiful child and a family facing a horrific diagnosis. Medical experts are disagreeing about the best course of action. 'We received a letter this morning from slightly more than a dozen experts in Batten disease from the United States who wrote to the (health) minister and I expressing that their perspective on this medication is that it would continue to provide benefit for patients, including for Charleigh, that are at the stage that she's at.' Eby said Health Minister Josie Osborne will likely have more to say on the matter on Friday. 2:15 Langford mom devastated after province pulls funding for daughter's expensive drug The letter from experts said they are concerned by the clinical and scientific justification used by B.C.'s ministry of health to terminate treatment for Charleigh. Story continues below advertisement Andrew McFadyen, executive director of the Issac Foundation in Toronto, which is a patient advocacy organization dedicated to supporting individuals living with rare diseases, was one of the experts who signed the letter to Eby and Osborne. He said they provided the same information to Osborne when they met with her a few weeks ago and he was appalled the government stopped funding the drug in the first place. 'So while this may not be overly new information, I think the idea that every single Batten disease expert in the world has signed on to say, we're unified, we agree, we're imploring you to change this decision, but we're also imploring you to look at developing new criteria so that this situation doesn't have to take place for other children across the country, but also around the world, like it did here now,' McFayden added.

CBC
6 hours ago
- CBC
B.C. limits sale of 2 more diabetes drugs used for weight loss
British Columbia's Ministry of Health is limiting the sales of two more diabetes drugs in an attempt to curb their off-label use for weight loss and preserve supply for people who are diabetic. The rule bans pharmacies from selling tirzepatide (sold as Mounjaro) and dulaglutide (sold as Trulicity) to non-Canadians or non-permanent residents who don't go in person to pick up the medications. The two drugs are being added to an existing regulation first announced in 2023, which limits sales of semaglutide, a medication sold under the brand names Ozempic, Wegovy, and Rybelsus. The medications are still available to non-Canadians with a valid prescription from a Canadian doctor or nurse practitioner as long as they go to pick up the medication in person, according to a statement from the ministry. They are also still available from B.C. pharmacies, online or in person, to B.C. residents, Canadian citizens and permanent residents who have a valid prescription. In January 2026, the Canadian patent for Ozempic will expire, paving the way for cheap generic versions of the semaglutide injections that help regulate blood sugar levels and appetite. Dr. Tom Elliott, medical director at B.C. Diabetes, says that semaglutide injections have revolutionized his practice, and they are astonishingly effective. Health Minister Josie Osborne says the drugs' use for weight loss is driving shortages in several countries, including the United States. "Tirzepatide, dulaglutide and semaglutide are prescription drugs approved for the management of Type 2 diabetes, but their off-label use for weight loss is driving shortages of the drugs in several countries, including the United States," she said in a press release.


Global News
8 hours ago
- Global News
Alberta health experts say wastewater testing may offer early detection of measles
Health experts embraced it as a valuable tool to help track the spread of COVID-19 during the pandemic. Now, those same experts say it may also help health officials get the jump on preventing measles outbreaks in places like Alberta, a province that now has the notorious reputation of having surpassed the entire United States for the number of lab-confirmed cases of the highly-infectious virus. 'I think surveillance is best when you have a number of different ways of following the disease and molecular testing of wastewater proved its worth during COVID,' said Alberta's former chief public health officer, Dr. James Talbot. 'It identifies when a virus has moved into new territory. It can be the earliest signal for that. It tells you whether the situation is getting better or worse, which is very important to know,' added Talbot. Story continues below advertisement 'And finally, when you're taking measures to control it, that kind of surveillance can tell you whether the measures are working or not.' 2:09 Data from wastewater helps ease Alberta's pandemic data problem Dr. Xiaoli Pang, a professor in the Department of Laboratory Medicine and Pathology at the University of Alberta, has been testing wastewater from 12 treatment plants across Alberta, once a week, since April 1. 'We never can replace clinical testing, because we are not able to detect who is infected, how many people are infected — we are just, through the community, (doing) population-based monitoring,' said Pang. Get weekly health news Receive the latest medical news and health information delivered to you every Sunday. Sign up for weekly health newsletter Sign Up By providing your email address, you have read and agree to Global News' Terms and Conditions and Privacy Policy Because the incubation period for measles can be up to three weeks — from exposure to the appearance of symptoms — Pang said the testing may be able to provide health officials with early detection of where outbreaks could occur, providing them with valuable information on where to focus their vaccination and education efforts. Story continues below advertisement The testing can also distinguish between the disease strain of measles and the strain used to produce the vaccine — which means it might also be useful to help determine how much of the population in a particular region has already been vaccinated. 'This disease is a predictable disease. If you apply a vaccine, you get protected, so that is important information for public health,' added Pang. One of the shortcomings of the wastewater testing is it likely does not accurately reflect the infection rate in babies or young children who may still use a diaper. According to the Alberta government, about a third of the people in the province infected with measles are under 5 years of age. But many health experts claim use of the existing system of clinical testing is likely also underestimating the size of the measles problem in Alberta. 'The surveillance system that's in place right now is likely to be undercounting the number of cases,' said Talbot, 'particularly in the summer, because there's so many opportunities during the summer for the measles virus to spread, as kids go to sports camps, Bible camps, family gatherings, summer camps and big events too, like the Calgary Stampede.' View image in full screen A special computerized device, installed over a modified manhole in Calgary, was used to help test for the Covid-19 virus during the pandemic. Global News Despite the promising results, however, Pang said the wastewater testing program is short on funding. Story continues below advertisement 'I'm only able to plan to monitor measles until end of this year,' said Pang. 'I believe this virus is (going to) continue to cause a huge problem and we may not be able to continue. 'So that is a challenge.' 2:05 COVID-19: What is wastewater testing, and how effective is it? Global News asked the Alberta government if it plans to use wastewater testing to help in the fight against measles. The Ministry of Primary and Preventative Health Services provided a written statement that said, 'public health officials are reviewing this data to determine its relevance during the current outbreak. However, because measles is a notifiable disease with clear, recognizable symptoms, the vast majority of cases are identified through routine public health surveillance.' The statement continued, 'At this stage, measles wastewater surveillance is considered an exploratory tool and is not anticipated to support earlier case detection, as public health already has a clear understanding of where cases are occurring and how the virus is spreading.' Story continues below advertisement Talbot, however, who has been highly critical of the province's efforts to prevent the spread of measles, believes wastewater testing could be another valuable tool for the province to use. 'You know, the provincial government is fond of saying that getting immunized is a personal decision, which of course it is,' said Talbot. 'But they never go on to make the second point, which is that although it's a personal decision, it has consequences for other people.'